Vistagen Therapeutics Inc (VTGN)

$3.65 +0.05 (1.39%)
Market Cap 111.98M
Revenue (ttm) 490,000.00
Net Income (ttm) -51.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,493.88%
Debt to Equity Ratio 0.00
Volume 505,900
Avg Vol 568,594
Day's Range N/A - N/A
Shares Out 30.68M
Stochastic %K 78%
Beta 0.55
Analysts Strong Sell
Price Target $13.00

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
JoshThe3rd
JoshThe3rd Oct. 4 at 6:04 PM
$VTGN Tight weekly base and buy volume coming in. I've heard the bull case. But what's the bear case/where it could wrong here for Palisade-3 in Q4 2025? I just like to hear all sides.
1 · Reply
SnoopDawg
SnoopDawg Oct. 4 at 5:25 PM
$VTGN there has been a lot of discussion among neuroscientists over the past few decades of just how many afferents of olfactory lobe there are and how critical these locations are including connections to learning and memory centers like hippocampus (my phd expertise) and the emotional centers including limbic system. In fact the strongest memory associations in mammalian systems are olfactory regulated. With this hard wired into our brains, its just a matter of time until someone kicks the door open with a functional therapy. If this trial succeeds on all endpoints it is a colossal win for neuroscience.
0 · Reply
jeannot9889
jeannot9889 Oct. 3 at 11:25 PM
$VTGN This one is about to explode.
0 · Reply
Supplement
Supplement Oct. 3 at 1:28 PM
$VTGN I believe Vistagen will me massively successful. I'm super bullish here.
0 · Reply
Heroforest
Heroforest Oct. 3 at 12:35 AM
$VTGN they still haven’t PR the last patient visit so I guess Readout most likely in December?
1 · Reply
Lucky72
Lucky72 Oct. 2 at 9:44 PM
$VTGN Maybe this stuff works.👍
0 · Reply
pops132005
pops132005 Oct. 2 at 2:29 PM
$VTGN what's happening lol the bulls took too much fasedinol. Wake up people!
1 · Reply
BioBum
BioBum Oct. 2 at 12:23 PM
$VTGN $4 is inevitable
1 · Reply
Wazaby44
Wazaby44 Oct. 2 at 10:32 AM
$VTGN the trend is clearly bullish but there is resistance at the 3.90s , lets break it today $$!
0 · Reply
Dan1019
Dan1019 Oct. 1 at 10:56 PM
$VTGN Everyone here seems to know more than the Insiders, the company's Phd's , Doctors, Researchers and whatnot, combined. You're either in or out. No Buts, Ands, Ifs!!!!!Just buy and hold on.
1 · Reply
Latest News on VTGN
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 8:30 AM EDT - 25 days ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Aug 8, 2025, 2:13 PM EDT - 2 months ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Aug 7, 2025, 4:30 PM EDT - 2 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 31, 2025, 8:30 AM EDT - 2 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 2 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jul 15, 2025, 8:30 AM EDT - 2 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 25, 2025, 8:30 AM EDT - 3 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 6:49 PM EDT - 3 months ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:30 PM EDT - 3 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 12, 2025, 8:30 AM EDT - 4 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Jun 2, 2025, 8:30 AM EDT - 4 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025, 8:30 AM EDT - 4 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025, 8:30 AM EDT - 4 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Apr 17, 2025, 8:30 AM EDT - 6 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 19, 2025, 8:30 AM EDT - 7 months ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 7 months ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 20, 2025, 8:30 AM EST - 8 months ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 14, 2025, 6:19 PM EST - 8 months ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Feb 13, 2025, 8:47 PM EST - 8 months ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 13, 2025, 4:30 PM EST - 8 months ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 6, 2025, 8:30 AM EST - 8 months ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Feb 5, 2025, 8:30 AM EST - 8 months ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 14, 2025, 8:30 AM EST - 9 months ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Jan 10, 2025, 8:30 AM EST - 9 months ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 11 months ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Nov 10, 2024, 7:43 AM EST - 11 months ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 7, 2024, 4:20 PM EST - 11 months ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Nov 5, 2024, 8:30 AM EST - 11 months ago

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Oct 15, 2024, 7:25 AM EDT - 1 year ago

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Sep 23, 2024, 8:30 AM EDT - 1 year ago

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Aug 13, 2024, 7:05 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Aug 13, 2024, 4:21 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Jul 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Jun 11, 2024, 6:41 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Jun 11, 2024, 4:20 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

Jun 7, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

Vistagen to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the Jefferies Global Healthcare Conference

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

May 23, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish

Mar 20, 2024, 9:01 PM EDT - 1 year ago

Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

Mar 17, 2024, 3:07 AM EDT - 1 year ago

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

This overlooked corner of women's health could be a $350 billion market opportunity

Mar 15, 2024, 2:33 PM EDT - 1 year ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY BTMD DARE

Vistagen to Present at Stifel 2024 Virtual CNS Days

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at Stifel 2024 Virtual CNS Days

JoshThe3rd
JoshThe3rd Oct. 4 at 6:04 PM
$VTGN Tight weekly base and buy volume coming in. I've heard the bull case. But what's the bear case/where it could wrong here for Palisade-3 in Q4 2025? I just like to hear all sides.
1 · Reply
SnoopDawg
SnoopDawg Oct. 4 at 5:25 PM
$VTGN there has been a lot of discussion among neuroscientists over the past few decades of just how many afferents of olfactory lobe there are and how critical these locations are including connections to learning and memory centers like hippocampus (my phd expertise) and the emotional centers including limbic system. In fact the strongest memory associations in mammalian systems are olfactory regulated. With this hard wired into our brains, its just a matter of time until someone kicks the door open with a functional therapy. If this trial succeeds on all endpoints it is a colossal win for neuroscience.
0 · Reply
jeannot9889
jeannot9889 Oct. 3 at 11:25 PM
$VTGN This one is about to explode.
0 · Reply
Supplement
Supplement Oct. 3 at 1:28 PM
$VTGN I believe Vistagen will me massively successful. I'm super bullish here.
0 · Reply
Heroforest
Heroforest Oct. 3 at 12:35 AM
$VTGN they still haven’t PR the last patient visit so I guess Readout most likely in December?
1 · Reply
Lucky72
Lucky72 Oct. 2 at 9:44 PM
$VTGN Maybe this stuff works.👍
0 · Reply
pops132005
pops132005 Oct. 2 at 2:29 PM
$VTGN what's happening lol the bulls took too much fasedinol. Wake up people!
1 · Reply
BioBum
BioBum Oct. 2 at 12:23 PM
$VTGN $4 is inevitable
1 · Reply
Wazaby44
Wazaby44 Oct. 2 at 10:32 AM
$VTGN the trend is clearly bullish but there is resistance at the 3.90s , lets break it today $$!
0 · Reply
Dan1019
Dan1019 Oct. 1 at 10:56 PM
$VTGN Everyone here seems to know more than the Insiders, the company's Phd's , Doctors, Researchers and whatnot, combined. You're either in or out. No Buts, Ands, Ifs!!!!!Just buy and hold on.
1 · Reply
Dan1019
Dan1019 Oct. 1 at 10:25 PM
$VTGN WTH???
0 · Reply
pops132005
pops132005 Oct. 1 at 8:02 PM
$VTGN sleepy day. Tmr we awaken!
0 · Reply
Stockrunner54
Stockrunner54 Oct. 1 at 1:42 PM
$VTGN she wants 3.90s !
0 · Reply
Angela51
Angela51 Sep. 30 at 11:32 PM
$VTGN Arnold 75, says to all his Homies, what’s up and how’s FUFRIDAYs been treating y’all. 👍🏼🇺🇸💪🏼
1 · Reply
MakesHerSquirt
MakesHerSquirt Sep. 30 at 10:16 PM
$VTGN Reasons why I think it's not going to pump very hard this time around. 1. Everyone is expecting it this time. 2. Short interest is not significant. 3. Everyone knows they need LOTS of money and will dump millions of shares on to the market. 4. Drug approval will be difficult under the JFK regime. 5. I want it to pump so hard. Prove me wrong go!
1 · Reply
cchurch
cchurch Sep. 30 at 9:18 PM
$VTGN what dat red candle
0 · Reply
highnihilism
highnihilism Sep. 30 at 10:06 AM
$HOOW Roundhill $HOOD Weeklypay ETF: 91 trades, $63K vs $40K avg (1.58x). $40K calls / $22K puts. $UL Unilever: 103 trades, $61K vs $129K avg (0.47x). $40K calls / $21K puts. $SANA Sana Biotechnology: 190 trades, $118K vs $97K avg (1.21x). $40K calls / $78K puts. $VTGN Vistagen Therapeutics: 102 trades, $43K vs $28K avg (1.57x). $40K calls / $3K puts.
0 · Reply
RemoteInvestor
RemoteInvestor Sep. 30 at 8:07 AM
$VTGN When do we expect "last patient dosed" press release?
1 · Reply
pops132005
pops132005 Sep. 29 at 11:25 PM
$VTGN
0 · Reply
Stockrunner54
Stockrunner54 Sep. 29 at 5:32 PM
$VTGN 3.90s by end of week ?
1 · Reply
MakesHerSquirt
MakesHerSquirt Sep. 29 at 3:42 PM
$VTGN
1 · Reply
Young_s
Young_s Sep. 29 at 3:41 PM
$VTGN https://clinicaltrials.gov/study/NCT06615557?spons=VistaGen%20Therapeutics,%20Inc.&rank=2&tab=history&a=7&b=8&compareMode=sideBySide#version-content-panel The report on PAL4 has been updated, but it doesn't seem to contain any significant information. I think I fixed the typo.
1 · Reply